20 results about "Skin medications" patented technology

A composition comprising: i) from 2% to 5% by weight of an aqueous solution comprising a hydrophilic active ingredient; ii) from 1% to 2% by weight of methyl glucose sesquistearate; iii) from 10% to 12% by weight of a polyglycerol-3 ester of a fatty acid; iv) at least 83% by weight of an ester oil selected from the group consisting of cetyl ethylhexanoate, isopropyl isostearate, and ethylhexyl palmitate; and wherein all weight percentages are based on the total weight of the composition; and wherein the sum of i), ii), iii) and iv) does not exceed 100% by weight. A method for dispersing a hydrophilic active ingredient in an oil. A cosmetic or dermatological pharmaceutical formulation comprising the initial composition. The invention also relates to a cosmetic or dermatological pharmaceutical formulation. A method of cosmetic, non-therapeutic treatment and / or care of skin, hair, nails and / or mucous membranes of a subject comprising topical application of a cosmetically effective amount of the composition.

The present disclosure is a peptide (Inpén SEQ ID N ° 1) with whitening action for melasma, a cosmetic or dermopharmaceutic composition containing this peptide as active ingredient and the use of this composition in the treatment of melasma or skin hyperpigmentation, developed from a peptide bioinspired from the venom of Brazilian wasps. Melasma is an acquired chronic dermatologic disorder characterized by the emergence of hyperpigmented skin spots. Although it is a common condition, a definitive cure has not been developed so far, due to the complexity of multifactorial causes. Because it is a cosmetic composition, of topic and painless application, the present disclosure can be applied daily, with no need for a specialist in the field of aesthetics, besides not being expensive as the known to date techniques for treating melasma are. The peptide SEQ ID N° 1 acts inhibiting melanogenesis.

The invention relates to the technical field of skin medicines, in particular to a pharmaceutical composition for preventing or treating inflammatory skin diseases and application. The invention discloses a pharmaceutical composition for preventing or treating inflammatory skin diseases and application. The composition comprises active ingredients of astacin and derivatives thereof, p-toluene sulfonamide and derivatives thereof, and pharmaceutically or cosmetically acceptable excipients. Through the synergistic effect of the two active components, the composition can effectively inhibit skin inflammatory response, relieve pruritus and erythema and promote skin barrier repair and wound healing. The composition can be prepared into multiple external dosage forms such as cream, gel and spray, is suitable for preventing or treating multiple inflammatory skin diseases such as atopic dermatitis, eczema and psoriasis, and can also be used for repairing and nursing skin wounds. The external formula provided by the invention has both curative effect and safety, and provides a new choice for the treatment of inflammatory dermatosis.

The present invention relates to a pharmaceutical composition, the pharmaceutical composition being a dermal pharmaceutical composition comprising the following components: a) a pharmaceutically acceptable carrier material, and b) pharmaceutically acceptable silver-modified bentonite which is accommodated in the pharmaceutically acceptable carrier material.

The invention discloses a terbinafine hydrochloride spray and a preparation method thereof, and relates to the technical field of pharmaceutical preparations. The terbinafine hydrochloride spray comprises the following components in percentage by weight: 0.5%-2% of terbinafine hydrochloride, 30%-60% of ethanol, 10%-20% of a solubilizer, 1%-5% of an absorption enhancer, 0.05%-0.2% of a pH regulator, 0.01%-0.05% of a preservative and the balance of water. In-vitro transdermal experiments show that the steady-state transdermal rate and the skin drug retention volume of the composition are obviously superior to those of a single absorption enhancer group and an enhancer-free group. Animal pharmacodynamic experiments prove that the spray disclosed by the invention has a remarkable improvement effect on skin lesion symptoms caused by fungal infection. The preparation process is simple, the preparation stability is good, the antifungal curative effect is remarkable, and the preparation has a good application prospect.

This invention provides a formulation and preparation method for an exosome-based skin medication. Taking the preparation of a 100g finished formulation as an example, it consists of active ingredients, a nanogel carrier, a composite stabilizer, a moisturizer, a pH adjuster, a preservative, and deionized water. By constructing a nanogel sustained-release system adapted to exosomes and a composite protection mechanism, the exosomes are stably and slowly released and efficiently absorbed on the skin surface within 7 days. This solves the problems of rapid release, low utilization rate, poor stability, and frequent reapplication required for exosome-based skin medications, thereby improving the skin care and treatment effects of exosomes.

The invention discloses licochalcone A flexible liposome and a preparation method thereof, and belongs to the field of pharmaceutics. The liposome is prepared from licochalcone A; soybean phospholipids; the invention relates to a skin care product, which is characterized by consisting of cholesterol and a membrane softener, wherein the membrane softener comprises isopropyl myristate (IPM) and polyoxyethylated castor oil (PCO). By adding IPM and PCO, the physical characteristics and transdermal performance of the liposome are improved, so that the medicine can penetrate through the skin and enter tissues, and the anti-inflammatory activity is better exerted. The liposome also has the excellent characteristics of small particle size, uniform distribution, high encapsulation efficiency, long storage period and the like, and has a good application prospect in the development of skin anti-inflammatory external medicines.

An antifungal drug airtight thin film patch is formed by bonding an airtight thin film layer, a viscous base layer and a drug layer from outside to inside, the airtight thin film layer is waterproof, isolates oxygen and blocks oxygen supply of superficial fungi so as to restrain growth of the fungi, the viscous base layer fixes the drug layer to the skin of an affected part, displacement caused by movement is avoided, and the drug layer is not prone to falling off. Fungi are killed through the antifungal drug of the drug layer. The air tightness of the film is utilized to reduce the skin breathing level of an affected part, inhibit the growth of related fungi, prevent the antifungal ointment or cream from quickly losing water or drying, ensure that the applied antifungal ointment or cream is always in a moist and moisture-sufficient state, prolong the skin medication time as much as possible, prevent the body temperature loss of the skin of the affected part, and improve the curative effect of the antifungal ointment or cream. The temperature of the skin of the affected part is increased, the antifungal drug is further promoted to diffuse to the deeper position of the skin of the affected part, pathogenic bacterium death is accelerated, the purpose of enhancing the antibacterial effect of the external antifungal drug is achieved, and meanwhile the awkward situation that unguent or cream is wiped off by clothes of a patient and cannot keep clean and sanitary is avoided by means of shielding of the airtight film.

The present invention relates to a topical skin medication composition and a pharmaceutical composition, each containing a mugwort-derived polydeoxyribonucleotide as an active ingredient.

The invention discloses a skin medicine fixing device based on negative pressure adsorption, which comprises an integrally formed sheet body and at least one sucking disc array arranged on the skin-friendly side of the sheet body, and the sucking discs are used for stably adsorbing the sheet body on the skin of a user; the suction cup is in a disc shape, the disc wall of the suction cup is of a big-end-down trapezoid structure, and the sheet body and the suction cup array are made of soft materials such as silica gel and polyurethane. The method has the beneficial effect that a series of adverse reactions caused by fixing by using a colloid material are avoided.

The disclosure is a peptide (Iaká (SEQ ID No1) with lightening action for periorbital hyperpigmentation, cosmetic or dermopharmaceutic composition containing this peptide and the use of this composition in the treatment of dark circles. Periorbital hyperpigmentation is a condition that does not add any risks to the patient's health state, however, it can cause aesthetic discomforts and appearance of tiredness. Dark circles can be formed due to anatomy or fat accumulation; due to a very thin skin thickness, allowing visualization of subcutaneous vessels; and, furthermore, due to melanin accumulation in the region. Due to this disclosure being a cosmetic composition, of topic non-invasive application, it can be applied daily without the requirement for an aesthetic specialist, besides not being as expensive as the currently known techniques for dark circles treatment. The peptide acts inhibiting melanogenesis.

The invention belongs to the technical field of tissue engineering skin and drug testing, and particularly relates to a regenerated skin drug testing method which comprises the following steps: firstly, collecting in-vitro human skin samples of different genders, ages and anatomical areas to establish a sample library, then selecting the samples according to test requirements, and dividing the samples into test samples and culture samples; a culture sample is used for 3D printing of regenerated skin, and through comparison of IVRT / IVPT test data of a test sample and a regenerated skin sample and multi-round optimization of a printing strategy, regenerated skin with the skin type close to that of in-vitro skin is finally manufactured in batches and used for tests of multiple drug application strategies. By optimizing the 3D printing strategy, the 3D printing regenerated skin manufactured in batches can reflect gender, age and anatomical area information more accurately, the use amount requirements of various drug application strategies are met, test errors are reduced, and challenges caused by the large use amount of the in-vitro skin are reduced.

This invention relates to a liquid azelaic acid salt, which is a room-temperature liquid salt produced by mixing azelaic acid with an amino-containing compound. The amino-containing compound is a primary, secondary, or tertiary amine; it does not contain a cyclic structure, has no more than 10 carbon atoms, and does not contain any amino-containing compounds that are prohibited or restricted from use in cosmetics or topical skin medications. The present invention forms a liquid salt by combining azelaic acid with several specific amino-containing compounds. Its typical characteristics are that it is a liquid salt at room temperature, possessing liquid properties, and can be directly applied to the skin. It can also be diluted and miscible with water or other solvents to prepare formulations, increasing the azelaic acid content in the formulation to an effective concentration. This effectively improves the solubility and compatibility of azelaic acid and solves the skin irritation problems caused by existing solubilizers.

To provide a material excellent in cell proliferation-promoting activity, hyaluronic acid production-promoting activity, MMP inhibitory activity, and collagen production-promoting activity.SOLUTION: An extract of Kochia scoparia is excellent in cell proliferation-promoting activity, hyaluronic acid production-promoting activity, MMP inhibitory activity, and collagen production-promoting activity, and also has excellent stability. The extract of Kochia scoparia of the present invention can be used not only in the field of beauty, such as in preventing skin aging, but also in the medical field, such as in suppressing functional decline due to aging, and is expected to be applicable to cosmetics, foods, quasi-drugs, pharmaceuticals, and the like.SELECTED DRAWING: None

The present invention relates to a pharmaceutical composition, wherein the pharmaceutical composition is a dermal pharmaceutical composition, and wherein the dermal pharmaceutical composition comprises the following components: a) a pharmaceutically acceptable carrier material, and b) pharmaceutically acceptable silver-modified bentonite incorporated in the pharmaceutically acceptable carrier material.

The present invention relates to a peptide (Indió SEQ ID No. 1) with botox-like action for the treatment and smoothing of wrinkles and expression lines, to a cosmetic or dermopharmaceutical composition containing this peptide as an active ingredient, and to use of this composition, developed from a bio-inspired peptide from the venom of social wasps. Wrinkles are natural characteristics of the physiological ageing of the skin, whether genetic or environmental. Currently, preventive routines and treatments are in high demand, but they can be costly or risky and may require supervision by a professional beautician. This cosmetic composition, being applied topically in a non-invasive and painless manner, can be used daily without the need for a specialist in the field, and is not as expensive as other well-known techniques. Peptide SEQ ID No. 1 acts by inhibiting the contraction of myoblasts.

The invention provides application of apocynin in preparation of a medicine for preventing and / or treating psoriasis, and belongs to the technical field of skin medicine preparation. The invention discloses application of apocynin in preparation of a medicine for preventing and / or treating psoriasis or psoriasis complications. A psoriasis mouse model is taken as an object, the drug effect of the apocynin is verified, and the apocynin can effectively relieve the phenotype of the psoriasis mouse model and inhibit the skin lesion progress and has a remarkable treatment effect on psoriasis. The invention provides a new medical application for apocynin, provides a new therapeutic drug for treating psoriasis, has a wide application prospect, and has a great clinical popularization value.

Use of an inducible extracellular vesicle as a medicament for skin, health care products or skin care products. A composition, comprising the inducible vesicle and the medicaments or care products for skin.

1. The name of this design product: Microneedle (Seal). 2. Purpose of this design product: used for the introduction and application of skin medications and cosmetic liquids. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention belongs to the technical field of cosmetics and skin medicine preparations, and particularly relates to a hydrogel composition containing elaeagnus conferta roxb, a preparation method of the hydrogel composition and a network pharmacology analysis and evaluation method. The composition is prepared from the following components: 1.5 to 2.5 percent w / v of sodium alginate, 0.5 to 1.5 percent w / v of hyaluronic acid, 4 to 6 percent w / v of glycerol, 0.2 to 0.3 percent w / v of ceramide, 0.4 to 0.6 percent w / v of glycyrrhizic acid, 0.05 to 0.15 percent w / v of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 0.2 to 0.3 percent w / v of sodium pyrrolidone carboxylate, 0.2 to 0.3 percent w / v of allantoin, 0.4 to 0.6 percent w / v of adenosine triphosphate and 0.5 to 5 percent w / v of elaeagnus conferta roxb extract. The invention systematically overcomes the technical resistance of unknown components, fuzzy mechanism, low dosage form efficiency and disjoint verification of the natural extract in the treatment of the specific dermatitis from the whole chain innovation of component analysis, mechanism verification, dosage form design and evaluation system.